About GTRQC Pilot
The GTRQC Pilot is the Genetic Testing Resource and Quality Consortium Pilot program supported by Blue Cross Blue Shield of Michigan and coordinated through the University of Michigan Medical School, Department of Pathology. The GTRQC Pilot is currently developing software tools aimed at improving the quality of care for patients who may be at elevated risk for hereditary cancer syndromes. Once completed, the software will be extensively tested, validated and evaluated for clinical utility through multiple testing processes: internal testing by the GTRQC Pilot staff, retrospective testing (using anonymized previously-assessed patients with known outcomes), concurrent testing (using consented patients), beta testing with the tools replacing currently used paper documents, and finally pilot testing at a variety of clinical sites to test the software with multiple patient populations and clinics.
We have completed the internal testing successfully with more than 600,000 patient scenarios run through our algorithms, each producing the expected results. In addition, 382 retrospective patient cases (mutation positive and negative) have been entered into the system with full concurrence to the patients' prior clinical recommendations.
Effectiven February 21, 2017, we began testing within the Michigan Medicine Breast and Ovarian Cancer Risk Evaluation Clinic with consented patients completing the InheRETTM Personal and Family Health Questionnaire. Once the clinic is confident that this tool works as intended, we will launch pilot testing in other sites, with a goal for a June 2017 launch.